Chain Drug Review - Requip reduces risk of dyskinesias
A recently released study shows that early treatment with the Parkinson’s disease drug Requip significantly reduces the risk of dyskinesias, involuntary body movements that are often associated with levodopa, a popular Parkinson’s therapy. SmithKline Beecham PLC received Food and Drug Administration approval for Requip, a second-generation dopamine agonist, about two years ago.
Related Results
Requip for RLSRequip now has generic competitorsGSK’s Requip significantly improves restless legs syndromeRequip shows use for restless legs syndrome. SKB, SkyePharma ink pact for once-daily Requip
COPYRIGHT 1999 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
